The diagnosis of AD is usually based on cognitive impairments relating to daily activities or positive physiopathologic markers of AD, such as an abnormal level of amyloid beta and/or tau in the cerebrospinal fluid (Dubois et al., 2014). Here, MAPT is linked to Alzheimer disease.